PMAM
IART icon

Picton Mahoney Asset Management’s Integra LifeSciences IART Stock Holding History

Picton Mahoney Asset Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,438
Closed -$60K – 702
2022
Q3 		$60K Buy
+1,438
New +$73.7K ﹤0.01% 578

Other funds holding IART

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Picton Mahoney Asset Management's IART Position: Q4 2022 in Review

Picton Mahoney Asset Management sold out of Integra LifeSciences (IART) in Q4 2022, closing a stake of 1,438 shares — an estimated $60K sold.

Picton Mahoney Asset Management first reported a position in IART in Q3 2022 and held it in 1 quarter. The position peaked at $60K in Q3 2022. 281 funds tracked by Wall St. Rank hold IART as of Q4 2022.

  • Picton Mahoney Asset Management reported no remaining Integra LifeSciences position as of Q4 2022 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 1,438 Integra LifeSciences shares in Q4 2022, an estimated $60K.
  • Picton Mahoney Asset Management first reported a position in Integra LifeSciences in Q3 2022 and held it in 1 quarter.
  • Picton Mahoney Asset Management's Integra LifeSciences position peaked at $60K in Q3 2022.
  • 281 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2022.

Based on Picton Mahoney Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.